新辅助化疗联合间歇性减瘤术对比初次减瘤术治疗FIGO III-IV期上皮性卵巢癌:系统综述与Meta分析
本系统综述与Meta分析纳入5项III期随机对照试验(n=2380),比较FIGO III-IV期上皮性卵巢癌患者接受初次减瘤术(PDS)与新辅助化疗后间歇性减瘤术(NACT-IDS)的生存与围手术期结局。结果显示两组总生存(OS)和无进展生存(PFS)无显著差异,但NACT-IDS组严重围手术期并发症更少且CC-0切除率更高。
要点
- NACT-IDS与PDS在OS(HR 1.00;95%CI 0.90-1.12)和PFS(HR 1.03;95%CI 0.92-1.16)上无显著差异。
- NACT-IDS组≥3级围手术期并发症显著更少(RR 0.43;95%CI 0.25-0.74)。
- NACT-IDS组CC-0切除率更高(RR 2.02;95%CI 1.26-3.24)。
核心结论
- 在FIGO III-IV期上皮性卵巢癌中,NACT-IDS与PDS的OS和PFS相似。
- NACT-IDS提高完全肉眼切除率并降低严重围手术期并发症。
- 初次手术可能应保留给预计可完全切除且并发症风险低的患者。
研究设计与样本
- 系统综述与Meta分析,纳入5项III期随机对照试验(n=2380例女性),包括1项仅会议报告。
- 检索MEDLINE、Embase、CENTRAL、Web of Science、Scopus、Cochrane Library及主要会议论文集(至2025年7月13日)。
- 采用随机效应模型合并OS/PFS的风险比(HR)和二分结局的风险比(RR),用I²统计量量化异质性。
- 遵循PRISMA,两名评价者独立筛选、提取数据并评估偏倚风险(RoB 1)。
- 方案注册于PROSPERO(CRD420251056445)。
主要发现
- NACT-IDS对比PDS的OS无差异(HR 1.00;95%CI 0.90-1.12;I²=16%)。
- NACT-IDS对比PDS的PFS无差异(HR 1.03;95%CI 0.92-1.16;I²=39%)。
- NACT-IDS组≥3级围手术期并发症显著更少(RR 0.43;95%CI 0.25-0.74;I²=75%)。
- NACT-IDS组CC-0率更高(RR 2.02;95%CI 1.26-3.24;I²=94%)。
临床怎么用
- 对于FIGO III-IV期上皮性卵巢癌,NACT-IDS可作为与PDS等效生存且围手术期安全性更优的选择。
- 初次减瘤术应优先考虑预计能实现完全切除且并发症风险低的患者。
局限性
- 纳入研究存在异质性(CC-0率I²=94%,≥3级并发症I²=75%)。
- 纳入1项仅会议报告,可能缺乏完整数据。
- 未报告其他可能影响结论的亚组或敏感性分析细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare survival and perioperative outcomes of Primary debulking surgery (PDS) versus neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) in newly diagnosed FIGO stage III-IV ovarian cancer. Primary outcomes were overall survival (OS) and progression-free survival (PFS). DATA SOURCES: MEDLINE, Embase, CENTRAL, Web of Science, Scopus, Cochrane Library, major conference proceedings (inception to July 13, 2025) STUDY SELECTION: Phase-III randomized trials comparing survival outcomes between PDS and NACT-IDS, enrolling adults with newly diagnosed stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer. DATA EXTRACTION AND SYNTHESIS: Following PRISMA, two reviewers independently screened, extracted and assessed risk-of-bias (RoB 1). Random-effects meta-analysis estimated pooled hazard ratios (HRs) for OS/PFS and risk ratios (RRs) for binary endpoints. Heterogeneity was quantified with the I² statistic. PROTOCOL: PROSPERO (CRD420251056445). RESULTS: Five RCTs (n = 2380 women), including one conference-only report, met criteria. NACT-IDS yielded no difference in OS (HR 1.00; 95 % CI 0.90-1.12; I² = 16 %) and PFS (HR 1.03; 95 % CI 0.92-1.16; I² = 39 %) versus PDS. Grade ≥ 3 perioperative complications were significantly less frequent with NACT-IDS (RR 0.43; 95 % CI 0.25-0.74; I² = 75 %) while CC-0 rates were higher (RR 2.02; 95 % CI 1.26-3.24; I² = 94 %). CONCLUSIONS: In FIGO stage III-IV, NACT-IDS achieves survival endpoints similar to PDS, while increasing the likelihood of complete macroscopic resection and reducing severe perioperative morbidity. Upfront surgery in advanced ovarian cancer management should likely be reserved for patients with feasible complete resection and presumed low morbidity.
引用
- Secchi M, Signorelli M, Rulli E, et al. Neoadjuvant chemotherapy followed by interval surgery versus primary debulking surgery in FIGO stage III-IV epithelial ovarian cancer: A systematic review and meta-analysis. Eur J Cancer. 2025. PMID: 41259943. doi:10.1016/j.ejca.2025.116116
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。